Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis

OncoImmunology

Volumn 5, Issue 2, 2016, Pages

  Garg, Abhishek D ^a   De Ruysscher, Dirk ^b   Agostinis, Patrizia ^a  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Anti tumor immunity; biomarkers; immunogenicity; inflammation; overall survival; prognostic factor; prognostics

Indexed keywords

EID: 84959387168     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1069938     Document Type: Article

References (75)

1. G.Kroemer, L.Galluzzi, O.Kepp, L.Zitvogel. Immunogenic cell death in cancer therapy. Annual review of immunology 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
2. A.D.Garg, S.Martin, J.Golab, P.Agostinis. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ 2014; 21:26-38; PMID:23686135; http://dx.doi.org/10.1038/cdd.2013.48
3. D.V.Krysko, A.D.Garg, A.Kaczmarek, O.Krysko, P.Agostinis, P.Vandenabeele. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-75; PMID:23151605; http://dx.doi.org/10.1038/nrc3380
4. H.Bugaut, M.Bruchard, H.Berger, V.Derangere, L.Odoul, R.Euvrard, S.Ladoire, F.Chalmin, F.Vegran, C.Rebe et al. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. PLoS One 2013; 8:e65181; PMID:23762310; http://dx.doi.org/10.1371/journal.pone.0065181
5. H.Angell, J.Galon. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013; 25:261-7; PMID:23579076; http://dx.doi.org/10.1016/j.coi.2013.03.004
6. J.Galon, B.Mlecnik, G.Bindea, H.K.Angell, A.Berger, C.Lagorce, A.Lugli, I.Zlobec, A.Hartmann, C.Bifulco et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 2014; 232:199-209; PMID:24122236; http://dx.doi.org/10.1002/path.4287
7. C.Sotiriou, M.J.Piccart. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007; 7:545-53; PMID:17585334; http://dx.doi.org/10.1038/nrc2173
8. S.Anguille, E.L.Smits, E.Lion, V.F.van Tendeloo, Z.N.Berneman. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014; 15:e257-67; PMID:24872109; http://dx.doi.org/10.1016/S1470-2045(13)70585-0
9. L.Galluzzi, E.Vacchelli, J.M.Bravo-San Pedro, A.Buque, L.Senovilla, E.E.Baracco, N.Bloy, F.Castoldi, J.P.Abastado, P.Agostinis et al. Classification of current anticancer immunotherapies. Oncotarget 2014; 5:12472-508; PMID:25537519; http://dx.doi.org/10.18632/oncotarget.2998
10. J.P.Brunet, P.Tamayo, T.R.Golub, J.P.Mesirov. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci USA 2004; 101:4164-9; PMID:15016911; http://dx.doi.org/10.1073/pnas.0308531101
11. W.Y.Cheng, T.H.Ou Yang, D.Anastassiou. Biomolecular events in cancer revealed by attractor metagenes. PLoS computational biology 2013; 9:e1002920; PMID:23468608; http://dx.doi.org/10.1371/journal.pcbi.1002920
12. E.Huang, S.H.Cheng, H.Dressman, J.Pittman, M.H.Tsou, C.F.Horng, A.Bild, E.S.Iversen, M.Liao, C.M.Chen et al. Gene expression predictors of breast cancer outcomes. Lancet 2003; 361:1590-6; PMID:12747878; http://dx.doi.org/10.1016/S0140-6736(03)13308-9
13. G.Stoll, D.Enot, B.Mlecnik, J.Galon, L.Zitvogel, G.Kroemer. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. Oncoimmunology 2014; 3:e27884; PMID:24790795; http://dx.doi.org/10.4161/onci.27884
14. O.Kepp, L.Senovilla, I.Vitale, E.Vacchelli, S.Adjemian, P.Agostinis, L.Apetoh, F.Aranda, V.Barnaba, N.Bloy et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3:e955691; PMID:25941621; http://dx.doi.org/10.4161/21624011.2014.955691
15. A.M.Dudek-Peric, G.B.Ferreira, A.Muchowicz, J.Wouters, N.Prada, S.Martin, S.Kiviluoto, M.Winiarska, L.Boon, C.Mathieu et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res 2015; 75:1603-14; PMID:25762540; http://dx.doi.org/10.1158/0008-5472.CAN-14-2089
16. A.D.Garg, A.M.Dudek, G.B.Ferreira, T.Verfaillie, P.Vandenabeele, D.V.Krysko, C.Mathieu, P.Agostinis. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy 2013; 9:1292-307; PMID:23800749; http://dx.doi.org/10.4161/auto.25399
17. A.D.Garg, D.V.Krysko, T.Verfaillie, A.Kaczmarek, G.B.Ferreira, T.Marysael, N.Rubio, M.Firczuk, C.Mathieu, A.J.Roebroek et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31:1062-79; PMID:22252128; http://dx.doi.org/10.1038/emboj.2011.497
18. T.Panaretakis, O.Kepp, U.Brockmeier, A.Tesniere, A.C.Bjorklund, D.C.Chapman, M.Durchschlag, N.Joza, G.Pierron, P.van Endert et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28:578-90; PMID:19165151; http://dx.doi.org/10.1038/emboj.2009.1
19. L.Senovilla, I.Vitale, I.Martins, M.Tailler, C.Pailleret, M.Michaud, L.Galluzzi, S.Adjemian, O.Kepp, M.Niso-Santano et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi.org/10.1126/science.1224922
20. L.Menger, E.Vacchelli, S.Adjemian, I.Martins, Y.Ma, S.Shen, T.Yamazaki, A.Q.Sukkurwala, M.Michaud, G.Mignot et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 2012; 4:143ra99; PMID:22814852; http://dx.doi.org/10.1126/scitranslmed.3003807
21. I.Martins, Y.Wang, M.Michaud, Y.Ma, A.Q.Sukkurwala, S.Shen, O.Kepp, D.Metivier, L.Galluzzi, J.L.Perfettini et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 2014; 21:79-91; PMID:23852373; http://dx.doi.org/10.1038/cdd.2013.75
22. L.Apetoh, F.Ghiringhelli, A.Tesniere, M.Obeid, C.Ortiz, A.Criollo, G.Mignot, M.C.Maiuri, E.Ullrich, P.Saulnier et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.1038/nm1622
23. A.D.Garg, A.M.Dudek, P.Agostinis. Calreticulin surface exposure is abrogated in cells lacking, chaperone-mediated autophagy-essential gene, LAMP2A. Cell Death Dis 2013; 4:e826; PMID:24091669; http://dx.doi.org/10.1038/cddis.2013.372
24. S.Martin, A.M.Dudek-Peric, H.Maes, A.D.Garg, M.Gabrysiak, S.Demirsoy, J.V.Swinnen, P.Agostinis. Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells. Biochem Pharmacol 2015; 93:290-304; PMID:25529535; http://dx.doi.org/10.1016/j.bcp.2014.12.003
25. Y.Ma, L.Aymeric, C.Locher, S.R.Mattarollo, N.F.Delahaye, P.Pereira, L.Boucontet, L.Apetoh, F.Ghiringhelli, N.Casares et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011; 208:491-503; PMID:21383056; http://dx.doi.org/10.1084/jem.20100269
26. Y.Ma, S.Adjemian, S.R.Mattarollo, T.Yamazaki, L.Aymeric, H.Yang, J.P.Portela Catani, D.Hannani, H.Duret, K.Steegh et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729-41; PMID:23562161; http://dx.doi.org/10.1016/j.immuni.2013.03.003
27. M.Michaud, I.Martins, A.Q.Sukkurwala, S.Adjemian, Y.Ma, P.Pellegatti, S.Shen, O.Kepp, M.Scoazec, G.Mignot et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science.1208347
28. R.Q.Peng, Y.B.Chen, Y.Ding, R.Zhang, X.Zhang, X.J.Yu, Z.W.Zhou, Y.X.Zeng, X.S.Zhang. Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J Gastroenterol 2010; 16:2428-34; PMID:20480531; http://dx.doi.org/10.3748/wjg.v16.i19.2428
29. + T cells. Cell Death Differ 2014; 21(12):1825-37; PMID:25012502; http://dx.doi.org/10.1038/cdd.2014.96
30. M.P.Chao, S.Jaiswal, R.Weissman-Tsukamoto, A.A.Alizadeh, A.J.Gentles, J.Volkmer, K.Weiskopf, S.B.Willingham, T.Raveh, C.Y.Park et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010; 2:63ra94; PMID:21178137; http://dx.doi.org/10.1126/scitranslmed.3001375
31. M.Wemeau, O.Kepp, A.Tesniere, T.Panaretakis, C.Flament, S.De Botton, L.Zitvogel, G.Kroemer, N.Chaput. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis 2010; 1:e104; PMID:21368877; http://dx.doi.org/10.1038/cddis.2010.82
32. L.Apetoh, F.Ghiringhelli, A.Tesniere, A.Criollo, C.Ortiz, R.Lidereau, C.Mariette, N.Chaput, J.P.Mira, S.Delaloge et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220:47-59; PMID:17979839; http://dx.doi.org/10.1111/j.1600-065X.2007.00573.x
33. Y.N.Fahmueller, D.Nagel, R.T.Hoffmann, K.Tatsch, T.Jakobs, P.Stieber, S.Holdenrieder. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer 2013; 132:2349-58; PMID:23047645; http://dx.doi.org/10.1002/ijc.27894
34. C.Wittwer, S.Boeck, V.Heinemann, M.Haas, P.Stieber, D.Nagel, S.Holdenrieder. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer 2013; 133:2619-30; PMID:23729200; http://dx.doi.org/10.1002/ijc.28294
35. G.L.Yang, L.H.Zhang, J.J.Bo, X.J.Huo, H.G.Chen, M.Cao, D.M.Liu, Y.R.Huang. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol 2012; 106:57-61; PMID:22237993; http://dx.doi.org/10.1002/jso.23040
36. A.D.Garg, A.M.Dudek, P.Agostinis. Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors 2013; 39:355-67; PMID:23900966; http://dx.doi.org/10.1002/biof.1125
37. J.Galon, H.K.Angell, D.Bedognetti, F.M.Marincola. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11-26; PMID:23890060; http://dx.doi.org/10.1016/j.immuni.2013.07.008
38. B.Gyorffy, P.Surowiak, J.Budczies, A.Lanczky. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 2013; 8:e82241; PMID:24367507; http://dx.doi.org/10.1371/journal.pone.0082241
39. B.Gyorffy, A.Lanczky, A.C.Eklund, C.Denkert, J.Budczies, Q.Li, Z.Szallasi. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010; 123:725-31; PMID:20020197; http://dx.doi.org/10.1007/s10549-009-0674-9
40. B.Gyorffy, A.Lanczky, Z.Szallasi. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 2012; 19:197-208; PMID:22277193; http://dx.doi.org/10.1530/ERC-11-0329
41. G.Stoll, G.Bindea, B.Mlecnik, J.Galon, L.Zitvogel, G.Kroemer. Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. Oncotarget 2015; 6:11894-909; PMID:26059437; http://dx.doi.org/10.18632/oncotarget.4180
42. J.L.Dennis, T.R.Hvidsten, E.C.Wit, J.Komorowski, A.K.Bell, I.Downie, J.Mooney, C.Verbeke, C.Bellamy, W.N.Keith et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005; 11:3766-72; PMID:15897574; http://dx.doi.org/10.1158/1078-0432.CCR-04-2236
43. E.Szegezdi, S.E.Logue, A.M.Gorman, A.Samali. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO reports 2006; 7:880-5; PMID:16953201; http://dx.doi.org/10.1038/sj.embor.7400779
44. E.K.Bartlett, P.A.Fetsch, A.C.Filie, A.Abati, S.M.Steinberg, J.R.Wunderlich, D.E.White, D.J.Stephens, F.M.Marincola, S.A.Rosenberg et al. Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration. Clin Cancer Res 2014; 20:2607-16; PMID:24647571; http://dx.doi.org/10.1158/1078-0432.CCR-13-2690
45. G.Bindea, B.Mlecnik, M.Tosolini, A.Kirilovsky, M.Waldner, A.C.Obenauf, H.Angell, T.Fredriksen, L.Lafontaine, A.Berger et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782-95; PMID:24138885; http://dx.doi.org/10.1016/j.immuni.2013.10.003
46. K.A.Mowen, M.David. Unconventional post-translational modifications in immunological signaling. Nature immunology 2014; 15:512-20; PMID:24840982; http://dx.doi.org/10.1038/ni.2873
47. M.Cascante, S.Marin. Metabolomics and fluxomics approaches. Essays Biochem 2008; 45:67-81; PMID:18793124; http://dx.doi.org/10.1042/BSE0450067
48. J.P.Bellocq, E.Luporsi, J.Barriere, J.Bonastre, J.Chetritt, A.G.Le Corroller, P.de Cremoux, F.Fina, A.S.Gauchez, D.Kassab-Chahmi et al. uPA/PAI-1, Oncotype DX, MammaPrint((R)). Prognosis and predictive values for clinical utility in breast cancer management. Annales de pathologie 2014; 34:349-51; PMID:25439987; http://dx.doi.org/10.1016/j.annpat.2014.04.010
49. J.N.Weinstein, E.A.Collisson, G.B.Mills, K.R.Shaw, B.A.Ozenberger, K.Ellrott, I.Shmulevich, C.Sander, J.M.Stuart. The cancer genome atlas pan-cancer analysis project. Nat Genet 2013; 45:1113-20; PMID:24071849; http://dx.doi.org/10.1038/ng.2764
50. T.Barrett, S.E.Wilhite, P.Ledoux, C.Evangelista, I.F.Kim, M.Tomashevsky, K.A.Marshall, K.H.Phillippy, P.M.Sherman, M.Holko et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res 2013; 41:D991-5; PMID:23193258; http://dx.doi.org/10.1093/nar/gks1193
51. M.L.Ascierto, M.Kmieciak, M.O.Idowu, R.Manjili, Y.Zhao, M.Grimes, C.Dumur, E.Wang, V.Ramakrishnan, X.Y.Wang et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 2012; 131:871-80; PMID:21479927; http://dx.doi.org/10.1007/s10549-011-1470-x
52. Q.Li, N.J.Birkbak, B.Gyorffy, Z.Szallasi, A.C.Eklund. Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics 2011; 12:474; PMID:22172014; http://dx.doi.org/10.1186/1471-2105-12-474
53. Y.Wang, J.G.Klijn, Y.Zhang, A.M.Sieuwerts, M.P.Look, F.Yang, D.Talantov, M.Timmermans, M.E.Meijer-van Gelder, J.Yu et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365:671-9; PMID:15721472; http://dx.doi.org/10.1016/S0140-6736(05)70933-8
54. E.Riquelme, M.Suraokar, C.Behrens, H.Y.Lin, L.Girard, M.B.Nilsson, G.Simon, J.Wang, K.R.Coombes, J.J.Lee et al. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res 2014; 20:3849-61; PMID:24850841; http://dx.doi.org/10.1158/1078-0432.CCR-13-1916
55. M.Sato, J.E.Larsen, W.Lee, H.Sun, D.S.Shames, M.P.Dalvi, R.D.Ramirez, H.Tang, J.M.DiMaio, B.Gao et al. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res 2013; 11:638-50; PMID:23449933; http://dx.doi.org/10.1158/1541-7786.MCR-12-0634-T
56. K.Yoshihara, T.Tsunoda, D.Shigemizu, H.Fujiwara, M.Hatae, H.Masuzaki, H.Katabuchi, Y.Kawakami, A.Okamoto, T.Nogawa et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res 2012; 18:1374-85; PMID:22241791; http://dx.doi.org/10.1158/1078-0432.CCR-11-2725
57. C.P.Goswami, H.Nakshatri. PROGgeneV2: enhancements on the existing database. BMC cancer 2014; 14:970; PMID:25518851; http://dx.doi.org/10.1186/1471-2407-14-970
58. E.Cerami, J.Gao, U.Dogrusoz, B.E.Gross, S.O.Sumer, B.A.Aksoy, A.Jacobsen, C.J.Byrne, M.L.Heuer, E.Larsson et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Dis 2012; 2:401-4; PMID:22588877; http://dx.doi.org/10.1158/2159-8290.CD-12-0095
59. S.Mukherjee, M.Heinonen, M.Dequvire, T.Sipila, P.Pulkkinen, K.Yrjala. Secondary succession of bacterial communities and co-occurrence of phylotypes in oil-polluted Populus rhizosphere. Soil Biol Biochem 2013; 58:188-97; http://dx.doi.org/10.1016/j.soilbio.2012.11.018
60. M.J.de Hoon, S.Imoto, J.Nolan, S.Miyano. Open source clustering software. Bioinformatics 2004; 20:1453-4; PMID:14871861; http://dx.doi.org/10.1093/bioinformatics/bth078
61. A.J.Saldanha. Java Treeview–extensible visualization of microarray data. Bioinformatics 2004; 20:3246-8; PMID:15180930; http://dx.doi.org/10.1093/bioinformatics/bth349
62. D.Szklarczyk, A.Franceschini, S.Wyder, K.Forslund, D.Heller, J.Huerta-Cepas, M.Simonovic, A.Roth, A.Santos, K.P.Tsafou et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 2015; 43:D447-52; PMID:25352553; http://dx.doi.org/10.1093/nar/gku1003
63. M.Michaud, A.Q.Sukkurwala, I.Martins, S.Shen, L.Zitvogel, G.Kroemer. Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. OncoImmunology 2012; 1:393-5; PMID:22737627; http://dx.doi.org/10.4161/onci.19070
64. S.Loi, S.Pommey, B.Haibe-Kains, P.A.Beavis, P.K.Darcy, M.J.Smyth, J.Stagg. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A 2013; 110:11091-6; PMID:23776241; http://dx.doi.org/10.1073/pnas.1222251110
65. M.Obeid, A.Tesniere, F.Ghiringhelli, G.M.Fimia, L.Apetoh, J.L.Perfettini, M.Castedo, G.Mignot, T.Panaretakis, N.Casares et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523
66. R.Spisek, A.Charalambous, A.Mazumder, D.H.Vesole, S.Jagannath, M.V.Dhodapkar. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007; 109:4839-45; PMID:17299090; http://dx.doi.org/10.1182/blood-2006-10-054221
67. A.D.Garg, D.V.Krysko, P.Vandenabeele, P.Agostinis. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother 2012; 61:215-21; PMID:22193987; http://dx.doi.org/10.1007/s00262-011-1184-2
68. T.Panaretakis, N.Joza, N.Modjtahedi, A.Tesniere, I.Vitale, M.Durchschlag, G.M.Fimia, O.Kepp, M.Piacentini, K.U.Froehlich et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 2008; 15:1499-509; PMID:18464797; http://dx.doi.org/10.1038/cdd.2008.67
69. A.R.van Vliet, S.Martin, A.D.Garg, P.Agostinis. The PERKs of damage-associated molecular patterns mediating cancer immunogenicity: From sensor to the plasma membrane and beyond. Semin Cancer Biol 2015; 33:74-85; PMID:25882379; http://dx.doi.org/10.1016/j.semcancer.2015.03.010
70. G.Schiavoni, A.Sistigu, M.Valentini, F.Mattei, P.Sestili, F.Spadaro, M.Sanchez, S.Lorenzi, M.T.D'Urso, F.Belardelli et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71:768-78; PMID:21156650; http://dx.doi.org/10.1158/0008-5472.CAN-10-2788
71. N.Casares, M.O.Pequignot, A.Tesniere, F.Ghiringhelli, S.Roux, N.Chaput, E.Schmitt, A.Hamai, S.Hervas-Stubbs, M.Obeid et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-701; PMID:16365148; http://dx.doi.org/10.1084/jem.20050915
72. J.Fucikova, P.Kralikova, A.Fialova, T.Brtnicky, L.Rob, J.Bartunkova, R.Spisek. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71:4821-33; PMID:21602432; http://dx.doi.org/10.1158/0008-5472.CAN-11-0950
73. J.Fucikova, I.Moserova, I.Truxova, I.He`rmanova, I.Vancurova, S.Partlova, A.Fialova, L.Sojka, P.F.Cartron, M.Houska et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer 2014; 135:1165-77; PMID:24500981; http://dx.doi.org/10.1002/ijc.28766
74. F.Ghiringhelli, L.Apetoh, A.Tesniere, L.Aymeric, Y.Ma, C.Ortiz, K.Vermaelen, T.Panaretakis, G.Mignot, E.Ullrich et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.1038/nm.2028
75. C.Koks, A.D.Garg, M.Ehrhardt, M.Riva, L.Vandenberk, L.Boon, S.De Vleeschouwer, P.Agostinis, N.Graf, S.Van Gool. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer 2015; 136:E313-E25; PMID:25208916; http://dx.doi.org/10.1002/ijc.29202